{"entity":{"id":"lancet-haematology","kind":"journal","name":"The Lancet Haematology","aka":["Lancet Haematol"],"tldr":"The Lancet Haematology is the Lancet's haematology journal, publishing phase 2 and 3 trials in leukaemia, lymphoma and myeloma, transplant studies and global-access commentary on blood cancers.","summary":"The Lancet Haematology (Lancet Haematol) is the Lancet's haematology journal, appearing monthly since 2014 and published by Elsevier on a hybrid model. It publishes randomised and single-arm phase 2 and 3 trials in leukaemia, lymphoma and myeloma, including CAR-T and bispecific follow-up and MDS and myelofibrosis studies, together with transplant studies, long-term outcomes, Commissions on haematological care in low-income settings and global-access commentary on blood cancers. Its readers are haematologists and trialists who follow the clinical evidence in blood cancers. Within OnCo it is the journal of the phase 1/2 paper on talicabtagene autoleucel for relapsed or refractory B-cell malignancies, and it is where a reader would look for CAR-T and bispecific trial follow-up.","asOf":"2026-09-09","links":[{"label":"Lancet journals","url":"https://www.thelancet.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["clinical-trial","randomised-trial","relapsed-refractory"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.thelancet.com/journals/lanhae/home","issn":"2352-3026","scope":"haematology","access":"hybrid","founded":2014,"impactFactor":{"value":15.4,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["The Lancet Haematology","Lancet Haematology","Lancet Haematol"]},"route":"/journals/lancet-haematology/","neighbours":{"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"randomised-trial","kind":"term","name":"Randomised trial","route":"/terms/randomised-trial/"},{"id":"relapsed-refractory","kind":"term","name":"Relapsed / refractory (R/R)","route":"/terms/relapsed-refractory/"}],"person":[{"id":"elisabeth-schorb","kind":"person","name":"Elisabeth Schorb","route":"/people/elisabeth-schorb/"},{"id":"ruben-mesa","kind":"person","name":"Ruben Mesa","route":"/people/ruben-mesa/"},{"id":"valdas-peceliunas","kind":"person","name":"Valdas Pečeliūnas","route":"/people/valdas-peceliunas/"}],"paper":[{"id":"paper-cd19-multiple-myeloma-lancet-haematol-2019","kind":"paper","name":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","route":"/key-papers/paper-cd19-multiple-myeloma-lancet-haematol-2019/"},{"id":"paper-esphall2010-continuous-imatinib-biondi-lancet-haematol-2018","kind":"paper","name":"EsPhALL2010: continuous imatinib with chemotherapy in paediatric Philadelphia chromosome-positive ALL","route":"/key-papers/paper-esphall2010-continuous-imatinib-biondi-lancet-haematol-2018/"},{"id":"paper-ielsg32-matrix-induction-ferreri-lancet-haematol-2016","kind":"paper","name":"IELSG32 first randomisation: the MATRix regimen (methotrexate, cytarabine, thiotepa, rituximab) in primary CNS lymphoma","route":"/key-papers/paper-ielsg32-matrix-induction-ferreri-lancet-haematol-2016/"},{"id":"paper-ielsg32-wbrt-vs-asct-consolidation-ferreri-lancet-haematol-2017","kind":"paper","name":"IELSG32 second randomisation: whole-brain radiotherapy or autologous stem cell transplant as consolidation in primary CNS lymphoma","route":"/key-papers/paper-ielsg32-wbrt-vs-asct-consolidation-ferreri-lancet-haematol-2017/"},{"id":"paper-gisslinger-lancet-haematol","kind":"paper","name":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","route":"/key-papers/paper-gisslinger-lancet-haematol/"},{"id":"paper-zeidan-lancet-haematol","kind":"paper","name":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial","route":"/key-papers/paper-zeidan-lancet-haematol/"},{"id":"paper-jain-talicabtagene-lancet-haem-2025","kind":"paper","name":"Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study","route":"/key-papers/paper-jain-talicabtagene-lancet-haem-2025/"},{"id":"paper-zanubrutinib-cll-lancet-haematol-2021","kind":"paper","name":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","route":"/key-papers/paper-zanubrutinib-cll-lancet-haematol-2021/"}]}}